| All Releases
|
|---|
 |
Cytori Reports 2009 Financial Results
Mar 12, 2010
|
26.5 KB
|
| |
SAN DIEGO, Mar 12, 2010 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ:CYTX) is reporting its financial results for
the year ended December 31, 2009. More information on our commercial and
clinical progress is posted online in the 'March 2010 Shareholder
Letter' at http://ir.cytoritx.com/investorrelations/blog.
During 2009,...
|
|
|
Cytori Therapeutics Announces Spring 2010 Conference Schedule
Feb 26, 2010
|
9.7 KB
|
| |
SAN DIEGO, Feb 26, 2010 (BUSINESS WIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces their spring 2010
medical and investor conference schedule. The full schedule may be
accessed from the following link in the Investor Relations section of
Cytori's website: http://ir.cytoritx.com/InvestorRelations/blog.cfm.
About Cy...
|
|
|
Cytori to Webcast Fourth Quarter Financial Results and Investor Presentation
Feb 24, 2010
|
10.1 KB
|
| |
SAN DIEGO, Feb 24, 2010 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ: CYTX) will host a webcast to discuss their
year-end and fourth quarter financial results on Friday, March 12, 2010
at 10:30 AM Eastern Time. Prior to the webcast at approximately 7:00 AM
Eastern Time on March 12, Cytori will post a shareholder letter to ...
|
|
|
Cytori's StemSource(R) Cell Bank to Be Installed at Leading Cosmetic & Reconstructive Surgery Network in Japan
Jan 27, 2010
|
11.5 KB
|
| |
SAN DIEGO, Jan 27, 2010 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ: CYTX) received an order for a StemSource(R)
Cell Bank from Cosmetic Surgery Seishin in Japan. The Cell Bank includes
a StemSource(R) processing system along with all other equipment,
software, database, and protocols required to cryopreserve patients' ow...
|
|
|
Cytori Issued U.S. Patent for Cell-Enriched Fat Grafting; New Patent Protects Key Cytori Market
Jan 26, 2010
|
11.9 KB
|
| |
SAN DIEGO, Jan 26, 2010 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ:CYTX) today received U.S. Patent No.
7,651,684 (the '684 patent) which covers the Company's methods for
delivering adipose-derived stem and regenerative cell-enriched fat
grafts into patients. The '684 patent specifically covers cell-enriched
fat ...
|
|
|
Cell-Enriched Fat Grafts Improve Long Term Graft Retention in Preclinical Study
Jan 25, 2010
|
13.0 KB
|
| |
SAN DIEGO, Jan 25, 2010 (BUSINESS WIRE) -- Results from Cytori Therapeutics' (NASDAQ: CYTX) preclinical fat
grafting study have been published in the February issue of the Annals
of Plastic Surgery. This article, entitled "Supplementation of Fat
Grafts with Adipose-Derived Regenerative Cells (ADRCs) Improves
Long-Ter...
|
|
|
FDA Grants 510(k) Marketing Clearance for Cytori's PureGraft(TM) System; First & Only Device on Market for Aesthetic Body Contouring using Autologous Fat Grafts
Jan 8, 2010
|
11.6 KB
|
| |
SAN DIEGO, Jan 08, 2010 (BUSINESS WIRE) -- The FDA has granted Cytori Therapeutics (NASDAQ: CYTX) 510(k) marketing
clearance for its PureGraft(TM) System. Cytori will now launch the first
and only device in the United States cleared for aesthetic body
contouring using autologous fat. PureGraft(TM) allows a patient's own fat ...
|
|
|
Cytori to Webcast Presentation at the OneMedPlace Finance Forum 2010 on January 12
Jan 6, 2010
|
9.6 KB
|
| |
SAN DIEGO, Jan 06, 2010 (BUSINESS WIRE) -- Cytori Therapeutics, Inc., (NASDAQ: CYTX) will present and provide a
webcast of its corporate presentation at the OneMedPlace Finance Forum
2010 at 2:15 EST on Tuesday, January 12, 2010.
The audio webcast may be accessed under "Webcasts" in the Investor
Relations section of the Com...
|
|
|
Promising Results Reported in Cell-Enriched Breast Reconstruction Trial
Dec 12, 2009
|
17.6 KB
|
| |
SAN ANTONIO, Dec 12, 2009 (BUSINESS WIRE) -- Interim results from a European clinical trial, RESTORE 2, demonstrate
that cell-enriched breast reconstruction achieved a high rate of patient
and physician satisfaction and improvements in overall breast deformity
in lumpectomy patients. These results are based on six-month foll...
|
|
|
Why Cell-Enriched Fat Grafting is Safe & Effective: New Mechanistic Support in Preclinical Model
Dec 12, 2009
|
12.5 KB
|
| |
SAN ANTONIO, Dec 12, 2009 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ: CYTX) reported results from a preclinical
cell-enriched fat grafting study supporting the safety and efficacy of
Cytori's method for enriching fat grafts with adipose-derived
regenerative cells (ADRCs). The study tracked the expression of
impor...
|
|
|
Cytori Completes Enrollment in International Breast Cancer Reconstruction Study; Interim Data to Be Presented Dec. 12 at San Antonio Breast Cancer Symposium
Nov 16, 2009
|
11.0 KB
|
| |
SAN DIEGO, Nov 16, 2009 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ:CYTX) completed enrollment in a 70-patient,
international breast cancer reconstruction study, RESTORE 2. The study
is evaluating the use of cell-enriched fat grafting to restore
functional and cosmetic deformities in women who have undergone partial
...
|
|
|
Cytori Reports 3rd Quarter 2009 Financial Results
Nov 9, 2009
|
21.0 KB
|
| |
SAN DIEGO, Nov 09, 2009 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ:CYTX) is reporting its financial results for
the quarter and nine months ended September 30, 2009. More information
on commercial and clinical progress is posted online in the 'Q3
Shareholder Letter' at http://ir.cytoritx.com.
During the third quarter, t...
|
|
|
Shareholder Letter: 3rd Quarter Results
Nov 9, 2009
|
21.0 KB
|
| |
Third Quarter 2009 Results and Commercial and Clinical Update
Dear Shareholders,
There are two key areas to highlight in the third quarter 2009 commercial and clinical update.
First, our technology continued to reach more physicians' practices and patients than ever before. During the third quarter, 15 new ...
|
|
|
Cytori Therapeutics to Webcast Third Quarter Financial Results on November 9, 2009
Nov 2, 2009
|
9.6 KB
|
| |
SAN DIEGO, Nov 02, 2009 (BUSINESS WIRE) -- Cytori Therapeutics Inc. (NASDAQ: CYTX) will release and host a webcast
to discuss its third quarter financial results on Monday, November 9,
2009 at 10:30 AM Eastern Time. The webcast will be available both live
and by replay two hours after the call on the Company's website, under...
|
|
|
CORRECTING and REPLACING Cytori to Webcast Presentation at the 2009 BIOCOM Investor Conference on October 27
Oct 27, 2009
|
9.6 KB
|
| |
SAN DIEGO, Oct 27, 2009 (BUSINESS WIRE) -- In first graph, first sentence of release dated Oct. 22, 2009, the
presentation time should read: 1:00 PM PDT (sted 1:00 PM EDT).
The corrected release reads:
CYTORI TO WEBCAST PRESENTATION AT THE 2009 BIOCOM INVESTOR CONFERENCE
ON OCTOBER 27Cytori Therapeutics, Inc., (NASDAQ:CYTX) will p...
|
|
|
Cytori to Webcast Presentation at the 2009 BIOCOM Investor Conference on October 27
Oct 22, 2009
|
9.4 KB
|
| |
SAN DIEGO, Oct 22, 2009 (BUSINESS WIRE) -- Cytori Therapeutics, Inc., (NASDAQ:CYTX) will present and provide a
webcast of its corporate presentation at the 2009 BIOCOM Investor
Conference at 1:00 PM EDT on Tuesday, October 27, 2009.
The audio-visual webcast may be accessed under "Webcasts" in the
Investor Relations section ...
|
|
|
Celution Performance Improved w/New Software Release
Oct 22, 2009
|
9.0 KB
|
| |
Cytori has released an important Celution®800/CRS operating system upgrade, which improves performance and ease of operation. The upgrade broadens the potential number of procedures which may be performed using the Celution® System, shortens processing times, and improves the economics for our customers' practices. We expect this to accelerate t...
|
|
|
Adipose-Derived Stem and Regenerative Cells Show Potential in First-in-Man Treatment of Stress Urinary Incontinence
Oct 15, 2009
|
11.5 KB
|
| |
SAN DIEGO, Oct 15, 2009 (BUSINESS WIRE) -- Cytori (NASDAQ:CYTX) was informed that stem and regenerative cells from
a patient's own fat tissue were used to treat stress urinary
incontinence (SUI) as part of an investigator-initiated five patient
pilot study in Japan. The results, reported at the 7th Annual Meeting of
...
|
|
|
Cytori Reports Preclinical Results that Suggest Adipose-Derived Regenerative Cells may Reverse Periodontal Disease
Sep 14, 2009
|
10.8 KB
|
| |
SAN DIEGO, Sep 14, 2009 (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ:CYTX) reported results from their
preclinical study on the use of uncultured adipose-derived regenerative
cells (ADRCs) in the treatment of critical periodontal defects in a rat
model. The results suggest that the use of ADRCs may reverse the effects
...
|
|
|
Cytori Therapeutics Announces Fall U.S. Medical Conference Presentation Schedule; Interim RESTORE-2 Results to be Reported in December
Sep 9, 2009
|
9.7 KB
|
| |
SAN DIEGO, Sep 09, 2009 (BUSINESS WIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today its fall medical
conference presentation schedule. The Company will present clinical and
preclinical results on the use of adipose tissue-derived stem and
regenerative cells or will be exhibiting at the following U.S. meetings:...
|
|
|